Sandy Draper
Stock Analyst at Guggenheim
(2.95)
# 1,334
Out of 5,182 analysts
111
Total ratings
60.64%
Success rate
21.66%
Average return
Main Sectors:
Stocks Rated by Sandy Draper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Buy | $464 → $432 | $409.65 | +5.46% | 12 | Jul 24, 2024 | |
| EVH Evolent Health | Maintains: Hold | $34 → $28 | $3.62 | +673.48% | 10 | May 14, 2024 | |
| IQV IQVIA Holdings | Downgrades: Neutral | n/a | $158.98 | - | 8 | Feb 15, 2024 | |
| CRL Charles River Laboratories International | Downgrades: Neutral | n/a | $166.79 | - | 15 | Feb 15, 2024 | |
| GDRX GoodRx Holdings | Maintains: Buy | $8 → $10 | $2.32 | +331.03% | 4 | Aug 10, 2023 | |
| DOCS Doximity | Downgrades: Neutral | n/a | $24.57 | - | 3 | Aug 9, 2023 | |
| TOI The Oncology Institute | Maintains: Buy | $3 → $2 | $3.44 | -41.86% | 3 | Jun 16, 2023 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $271 → $263 | $102.49 | +156.61% | 13 | Apr 28, 2023 | |
| AGL agilon health | Maintains: Buy | $525 → $750 | $27.90 | +2,588.17% | 3 | Mar 6, 2023 | |
| HQY HealthEquity | Maintains: Buy | $89 → $94 | $81.18 | +15.79% | 11 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $6.00 | - | 10 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $51 | $24.84 | +105.31% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $143 → $129 | $200.17 | -35.55% | 2 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $55 | $33.43 | +64.52% | 2 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $12 | $27.91 | -57.00% | 1 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $5.50 | +809.09% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $9.02 | +620.62% | 1 | Jan 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $36 | $1.34 | +2,596.63% | 4 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $167 | $158.49 | +5.37% | 3 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.87 | - | 2 | May 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $63 | $9.05 | +596.52% | 1 | Sep 20, 2016 |
Medpace Holdings
Jul 24, 2024
Maintains: Buy
Price Target: $464 → $432
Current: $409.65
Upside: +5.46%
Evolent Health
May 14, 2024
Maintains: Hold
Price Target: $34 → $28
Current: $3.62
Upside: +673.48%
IQVIA Holdings
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $158.98
Upside: -
Charles River Laboratories International
Feb 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $166.79
Upside: -
GoodRx Holdings
Aug 10, 2023
Maintains: Buy
Price Target: $8 → $10
Current: $2.32
Upside: +331.03%
Doximity
Aug 9, 2023
Downgrades: Neutral
Price Target: n/a
Current: $24.57
Upside: -
The Oncology Institute
Jun 16, 2023
Maintains: Buy
Price Target: $3 → $2
Current: $3.44
Upside: -41.86%
ICON Public Limited Company
Apr 28, 2023
Maintains: Buy
Price Target: $271 → $263
Current: $102.49
Upside: +156.61%
agilon health
Mar 6, 2023
Maintains: Buy
Price Target: $525 → $750
Current: $27.90
Upside: +2,588.17%
HealthEquity
Dec 7, 2022
Maintains: Buy
Price Target: $89 → $94
Current: $81.18
Upside: +15.79%
Oct 24, 2022
Upgrades: Neutral
Price Target: n/a
Current: $6.00
Upside: -
Aug 12, 2022
Maintains: Buy
Price Target: $36 → $51
Current: $24.84
Upside: +105.31%
May 25, 2021
Maintains: Buy
Price Target: $143 → $129
Current: $200.17
Upside: -35.55%
May 18, 2021
Maintains: Buy
Price Target: $84 → $55
Current: $33.43
Upside: +64.52%
Apr 21, 2021
Initiates: Hold
Price Target: $12
Current: $27.91
Upside: -57.00%
Jan 28, 2021
Initiates: Buy
Price Target: $50
Current: $5.50
Upside: +809.09%
Jan 28, 2021
Initiates: Buy
Price Target: $65
Current: $9.02
Upside: +620.62%
May 13, 2020
Maintains: Buy
Price Target: $30 → $36
Current: $1.34
Upside: +2,596.63%
Mar 26, 2020
Maintains: Buy
Price Target: $175 → $167
Current: $158.49
Upside: +5.37%
May 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.87
Upside: -
Sep 20, 2016
Initiates: Buy
Price Target: $63
Current: $9.05
Upside: +596.52%